Longbio Pharma is founded in 2018, and located in Zhangjiang Hi-tech Park, Shanghai. There are 40+ scientists, 10+years experiences in protein drug development (antibodies and fusion proteins) .The co-founder team successfully developed two drugs for marketing (accumulated global sales USD 30 Billion). Longbio Pharma is focusing on R&D the innovative drugs of autoimmune and rare diseases (allergy and complement).
Location: China, Pudong
Investors 1
| Date | Name | Website |
| 10.07.2026 | Qiming Ven... | qimingvc.c... |
Mentions in press and media 14
| Date | Title | Description |
| 10.07.2026 | China’s Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange | - |
| 02.03.2026 | Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair® | PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and autoimmune diseases, proudly anno... |
| 03.03.2025 | Breakthrough! Exciting interim Phase II Data of LP-003 in CSU released by Longbio at AAAAI 2025 | SAN DIEGO, March 3, 2025 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio"), a leading biotech company dedicated to developing innovative biologic treatments for allergy, respiratory, dermatology, hematol... |
| 25.11.2024 | Food Allergy: LongBio's LP-003 achieves its fourth IND approval | SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- LongBio is proud to announce that the National Medical Products Administration (NMPA, China) has approved the Investigational New Drug (IND) application for LP-003, the company's next-generation anti-... |
| 27.09.2024 | LongBio's Series B2 Financing: A Leap Towards Innovative Biologics | In the bustling world of biotechnology, where innovation is the lifeblood, LongBio Pharma (Suzhou) Co., Ltd. has made headlines with its recent Series B2 financing. The Shanghai-based company, which is deep into the Phase III stage of drug ... |
| 24.09.2024 | LongBio Closes Series B2 Financing | LongBio, a Shanghai, China-based Phase III-stage biotech company focused on the R&D of antibody and fusion protein drugs for allergies and complement-mediated diseases, raised an undisclosed amount in Series B2 funding. The round was le... |
| 24.09.2024 | LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners | SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio" or the "Company"), a Phase III-stage biotech company focused on the R&D of innovative antibody and fusion protein drugs for allerg... |
| 16.04.2024 | Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024 | BUENOS AIRES, Argentina, April 16, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. (referred to as "LongBio"), a leading biotech company dedicated to developing innovative protein treatments for nephrology, allergy, respira... |
| 12.03.2024 | Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD | SAN DIEGO, March 12, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, ... |
| 26.02.2024 | Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024 | WASHINGTON, Feb. 26, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, ... |
Show more